Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment - Concepedia

Concepedia

Publication | Open Access

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

DOI Full Paper Access

123

Citations

17

References

2020

Year

Vince Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, Mark Löwenberg, Nanne K.H. de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M. Jansen, Alexander Bodelier,

Alimentary Pharmacology & Therapeutics

Abstract

Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti-TNF treatment.

References

	Year	Citations

Page 1